Celcuity (NASDAQ:CELC) Shares Gap Down – Here’s What Happened

Celcuity, Inc. (NASDAQ:CELC) gapped down prior to trading on Monday . The stock had previously closed at $107.51, but opened at $104.00. Celcuity shares last traded at $102.3480, with a volume of 61,047 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CELC shares. Stifel Nicolaus increased their price target on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC set a $95.00 target price on shares of Celcuity in a report on Monday, October 20th. Guggenheim started coverage on shares of Celcuity in a report on Monday, September 22nd. They issued a “buy” rating for the company. Wells Fargo & Company initiated coverage on shares of Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Price Performance

The firm has a market capitalization of $4.84 billion, a P/E ratio of -28.48 and a beta of 0.25. The business’s 50-day simple moving average is $96.59 and its 200 day simple moving average is $62.39. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.13. Sell-side analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insider Transactions at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the transaction, the director directly owned 7,260 shares in the company, valued at $702,259.80. This trade represents a 34.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Soleus Capital Management L.P. raised its holdings in Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after buying an additional 437,696 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock valued at $101,717,000 after acquiring an additional 391,262 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Celcuity by 9.8% during the second quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares during the last quarter. Saturn V Capital Management LP boosted its holdings in shares of Celcuity by 8.4% during the second quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after purchasing an additional 91,843 shares during the period. Finally, UBS Group AG grew its stake in shares of Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after purchasing an additional 769,891 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.